Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...
LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...
AstraZeneca raised its full-year guidance after third-quarter results topped analysts’ expectations, boosted by its cancer ...
The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...
AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but ...
6don MSN
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...
The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...
AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...
AstraZeneca chief Pascal Soriot has said a deepening criminal probe into his company’s Chinese business is being taken “very ...
Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p18,000.00. Justin Smith has given his Buy rating due to a combination of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback